934 related articles for article (PubMed ID: 27603132)
21. Dysregulated minor intron splicing in cancer.
Nishimura K; Yamazaki H; Zang W; Inoue D
Cancer Sci; 2022 Sep; 113(9):2934-2942. PubMed ID: 35766428
[TBL] [Abstract][Full Text] [Related]
22. Alternative-splicing defects in cancer: Splicing regulators and their downstream targets, guiding the way to novel cancer therapeutics.
Urbanski LM; Leclair N; Anczuków O
Wiley Interdiscip Rev RNA; 2018 Jul; 9(4):e1476. PubMed ID: 29693319
[TBL] [Abstract][Full Text] [Related]
23. RNA splicing, cell signaling, and response to therapies.
Abou Faycal C; Gazzeri S; Eymin B
Curr Opin Oncol; 2016 Jan; 28(1):58-64. PubMed ID: 26575690
[TBL] [Abstract][Full Text] [Related]
24. Biological relevance of alternative splicing in hematologic malignancies.
Szelest M; Giannopoulos K
Mol Med; 2024 May; 30(1):62. PubMed ID: 38760666
[TBL] [Abstract][Full Text] [Related]
25. Inhibition of SF3B1 by molecules targeting the spliceosome results in massive aberrant exon skipping.
Wu G; Fan L; Edmonson MN; Shaw T; Boggs K; Easton J; Rusch MC; Webb TR; Zhang J; Potter PM
RNA; 2018 Aug; 24(8):1056-1066. PubMed ID: 29844105
[TBL] [Abstract][Full Text] [Related]
26. Identification of spliceosome components pivotal to breast cancer survival.
An J; Luo Z; An W; Cao D; Ma J; Liu Z
RNA Biol; 2021 Jun; 18(6):833-842. PubMed ID: 32965163
[TBL] [Abstract][Full Text] [Related]
27. Characteristics of patients with myelodysplastic neoplasm and spliceosome mutations.
Urrutia S; Li Z; Almanza E; Bataller A; Kanagal-Shamanna R; Senapati J; Sasaki K; Chien K; Montalban-Bravo G; DiNardo C; Borthakur G; Bueso-Ramos C; Pierce S; Kantarjian H; Garcia-Manero G
Leukemia; 2023 Jun; 37(6):1397-1400. PubMed ID: 37185307
[No Abstract] [Full Text] [Related]
28. Splicing to Keep Cycling: The Importance of Pre-mRNA Splicing during the Cell Cycle.
Petasny M; Bentata M; Pawellek A; Baker M; Kay G; Salton M
Trends Genet; 2021 Mar; 37(3):266-278. PubMed ID: 32950269
[TBL] [Abstract][Full Text] [Related]
29. Variant snRNPs: New players within the spliceosome system.
Vazquez-Arango P; O'Reilly D
RNA Biol; 2018 Jan; 15(1):17-25. PubMed ID: 28876172
[TBL] [Abstract][Full Text] [Related]
30. Pan-cancer analysis identifies mutations in
Liu Z; Zhang J; Sun Y; Perea-Chamblee TE; Manley JL; Rabadan R
Proc Natl Acad Sci U S A; 2020 May; 117(19):10305-10312. PubMed ID: 32332164
[TBL] [Abstract][Full Text] [Related]
31. Splicing Dysregulation as Oncogenic Driver and Passenger Factor in Brain Tumors.
Bielli P; Pagliarini V; Pieraccioli M; Caggiano C; Sette C
Cells; 2019 Dec; 9(1):. PubMed ID: 31861467
[TBL] [Abstract][Full Text] [Related]
32. Alternative splicing and cancer metastasis: prognostic and therapeutic applications.
Marzese DM; Manughian-Peter AO; Orozco JIJ; Hoon DSB
Clin Exp Metastasis; 2018 Aug; 35(5-6):393-402. PubMed ID: 29845349
[TBL] [Abstract][Full Text] [Related]
33. Differential RNA splicing as a potentially important driver mechanism in multiple myeloma.
Bauer MA; Ashby C; Wardell C; Boyle EM; Ortiz M; Flynt E; Thakurta A; Morgan G; Walker BA
Haematologica; 2021 Mar; 106(3):736-745. PubMed ID: 32079689
[TBL] [Abstract][Full Text] [Related]
34. Splicing Factor Mutations in Cancer.
Bejar R
Adv Exp Med Biol; 2016; 907():215-28. PubMed ID: 27256388
[TBL] [Abstract][Full Text] [Related]
35. Mutations in spliceosomal proteins and retina degeneration.
Růžičková Š; Staněk D
RNA Biol; 2017 May; 14(5):544-552. PubMed ID: 27302685
[TBL] [Abstract][Full Text] [Related]
36. Identification and validation of critical alternative splicing events and splicing factors in gastric cancer progression.
Feng H; Jin Z; Liu K; Peng Y; Jiang S; Wang C; Hu J; Shen X; Qiu W; Cheng X; Zhao R
J Cell Mol Med; 2020 Nov; 24(21):12667-12680. PubMed ID: 32939931
[TBL] [Abstract][Full Text] [Related]
37. Targeting Splicing in the Treatment of Myelodysplastic Syndromes and Other Myeloid Neoplasms.
Brierley CK; Steensma DP
Curr Hematol Malig Rep; 2016 Dec; 11(6):408-415. PubMed ID: 27492253
[TBL] [Abstract][Full Text] [Related]
38. Exploiting differential RNA splicing patterns: a potential new group of therapeutic targets in cancer.
Jyotsana N; Heuser M
Expert Opin Ther Targets; 2018 Feb; 22(2):107-121. PubMed ID: 29235382
[TBL] [Abstract][Full Text] [Related]
39. Multilayered control of splicing regulatory networks by DAP3 leads to widespread alternative splicing changes in cancer.
Han J; An O; Ren X; Song Y; Tang SJ; Shen H; Ke X; Ng VHE; Tay DJT; Tan HQ; Kappei D; Yang H; Chen L
Nat Commun; 2022 Apr; 13(1):1793. PubMed ID: 35379802
[TBL] [Abstract][Full Text] [Related]
40. Therapeutic Applications of Targeted Alternative Splicing to Cancer Treatment.
Lin JC
Int J Mol Sci; 2017 Dec; 19(1):. PubMed ID: 29283381
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
